updated on February 23, 2025

• Theodore Worlanyo Asigbee's work was accepted in Microbiol. Spectr. (2025.1.31)

Asigbee, T.W., Nakamura-Hoshi, M., Kuse, N., Ishii, H., Ishikawa, K., Kawana-Tachikawa, A., Horibe, E., Nakashima, M., Yamano, Y., Uchimaru, K., and Matano, T.* Virus-host immune interaction in asymptomatic HTLV-1 carriers. Microbiol. Spectr. e0250724, Epub on Jan 31, 2025.

• Alitzel Anzurez reported her work in Jpn J Infect Dis. (2024.11.21)

Anzurez, A., Runtuwene, L., Dang, T.T.T., Nakayama-Hosoya, K., Koga, M., Yoshimura, Y., Sasaki, H., Miyata, N., Miyazaki, K., Takahashi, Y., Suzuki, T., Yotsuyanagi, H., Tachikawa, N., Matano, T., and Kawana-Tachikawa, A.* Characterization of the proinflammatory cytokine profile during acute SARS-CoV-2 infection in people with human immunodeficiency virus. Jpn. J. Infect. Dis. 77:301-310, 2024.

• Hiroshi Ishii made an oral lecture at HIVR4P2024, Lima, Peru, in October., 2024. (2024.10.12)

• Sayuri Seki reported her work in J. Biotechnol. (2024.8.10)

Virion-surface display of a chimeric immunoglobulin Fc domain facilitating uptake by antigen-presenting cells. J. Biotechnol. 391:57-63, 2024.

• Midori Nakamura-Hoshi reported her work in Mol. Ther. (2024.7.3)

Nakamura-Hoshi, M., Ishii, H., Nomura, T., Nishizawa, M., Hau, T.T.T., Kuse, N., Okazaki, M., Ainai, A., Suzuki, T., Hasegawa, H., Yoshida, T., Yonemitsu, K., Suzaki, Y., Ami, Y., Yamamoto, H., Matano, T. Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques. Mol. Ther., 32:2328-2339, 2024.

• Hiroshi Ishii and Aki Tanabe made oral presentations at HTLV Conference 2024, London, U.K., in June., 2024. (2024.6.6)

• Takeshi Yoshida reported his work in J. Virol. (2024.2.20)

Yoshida, T., Kasuya, Y., Yamamoto, H., Kawai, G., Hanaki, K.-i, Matano, T., and Masuda, T. HIV-1 RNAs whose transcription initiates from the third deoxyguanosine of GGG tract in the 5' long terminal repeat serve as a dominant genome for efficient provirus DNA formation. J. Virol., 98:e0182523, 2024.

• The result of a phase I clinical trial using SeV vector (S001) was reported in J. Infect. Dis. (2016.10.17)

Nyombayire, J., Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C.L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J.-L., Fast, P., Laufer, D.S., Cox, J.H., and the S001 Study Team. First-in-human evaluation of the safety and immunogenicity of a replicating intranasally administered Sendai HIV-1 Gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J. Infect. Dis., 215:95-104. 2017.

• GHIT has announced to the award for a project for development of a Dengue vaccine by VLP Therapeutics in collaboration with Nagasaki University and NIID. (2016.10.5)

This international collaborative project by VLP Therapeutics, Nagasaki University and National Institute of Infectious diseases (NIID), supported by Global Health Innovation Technology [GHIT] Fund, is a pre-clinical study to investigate safety and immunogenicity of a virus-like particle (VLP)-based vaccine against Dengue virus infection. 

    GHIT press room     GHIT web site     VLP Therapeutics web site

• The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations, England, Kenya and Rwanda. The SeV vector AIDS vaccine system has been developed by our research group. (2013.4.2)

 

     Information on this project in IAVI Web

>> AIDS Research Center website